Aktienanalyse zu Filana Therapeutics Inc (FLNA)FLNAFilana Therapeutics Inc

Filana Therapeutics, Inc., formerly Cassava Sciences, Inc., is a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, is an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood. It operates in the Healthcare sector.

Filana Therapeutics is a good buy right now due to its current price of $0.929, significantly below the analyst price target of $5, indicating a potential upside of over 438%. Additionally, the company has a current ratio of 2.08, suggesting it can cover its short-term liabilities comfortably. The main risk is its forward P/E ratio of 151.52, indicating high expectations for future earnings growth that may not be met.